Group 1 - The meeting of the eighth supervisory board of Huaren Pharmaceutical Co., Ltd. was held on August 14, 2025, in accordance with legal regulations and company bylaws [1][2] - The supervisory board approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's actual situation without any false records or misleading statements [1][2] - The supervisory board also approved the amendment of the company's articles of association, which aligns with the latest legal requirements and aims to enhance corporate governance [2]

Meeting Overview - The company will hold its first extraordinary general meeting of shareholders in 2025 on September 1, 2025, at 14:00 [1] - Shareholders can participate through on-site voting or online voting via the Shenzhen Stock Exchange systems [2] Voting Procedures - Shareholders can choose to vote either in person, through the Shenzhen Stock Exchange trading system, or the internet voting system, but not more than one method [2][4] - Voting will be conducted for eight non-cumulative proposals and one cumulative voting proposal [4] Meeting Agenda - The meeting will review proposals that have been approved by the company's board and supervisory committee [4] - Proposal 1 requires a special resolution with at least two-thirds of the voting rights present for approval [4] - Proposals 2 and 3 will involve individual voting on sub-proposals and cumulative voting for independent director candidates, respectively [4] Registration and Attendance - Natural person shareholders must present identification and shareholder account cards for registration [6] - Legal entity shareholders must provide relevant documentation, including a business license and authorization letters [6] - Remote shareholders can register via mail or email, but phone registrations are not accepted [6] Online Voting Instructions - Shareholders can vote online through the Shenzhen Stock Exchange trading system or the internet voting system [7] - Specific instructions for casting votes on both non-cumulative and cumulative proposals are provided [7][8]

Core Insights - Huaren Pharmaceutical reported a revenue of 623,896,434.45 yuan for the first half of 2025, representing a year-on-year decline of 19.13% [2] - The net profit attributable to shareholders of the listed company was 37,332,883.17 yuan, down 49.01% year-on-year [2] Financial Performance - Revenue for the first half of 2025: 623.90 million yuan, down 19.13% compared to the previous year [2] - Net profit for the same period: 37.33 million yuan, a decrease of 49.01% year-on-year [2]

Group 1 - The core point of the article is that Huaren Pharmaceutical reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges for the company [1] - The company's operating revenue for the first half of 2025 was approximately 623.9 million yuan, representing a year-on-year decrease of 19.13% [1] - The net profit attributable to shareholders of the listed company was about 37.3 million yuan, showing a year-on-year decline of 49.01% [1]

Core Viewpoint - Huaren Pharmaceutical (300110) announced the resignation of independent directors Zhang Tianxi and Feng Genfu, who have served since August 28, 2019, nearing six years of tenure [1] Group 1 - The board of directors received resignation reports from independent directors Zhang Tianxi and Feng Genfu [1] - Both directors will no longer hold any positions within the company after their resignation [1] - The resignations are in accordance with relevant regulations regarding independent director tenure [1]

证券日报网讯 8月15日晚间，华仁药业发布公告称，公司第八届董事会第九次会议审议通过了《及摘 要》等多项议案。 （文章来源：证券日报） ...

证券日报网讯 8月15日晚间，华仁药业发布公告称，公司第八届监事会第七次会议审议通过了《及摘 要》《关于修订的议案》。 （文章来源：证券日报） ...

智通财经APP讯，华仁药业(300110.SZ)发布2025年半年度报告，报告期内，公司实现营业收入6.24亿 元，同比下降19.13%。实现归属于上市公司股东的净利润3733.29万元，同比下降49.01%。实现归属于 上市公司股东的扣除非经常性损益的净利润2768.92万元，同比下降59.17%。基本每股收益0.0316元。 ...

格隆汇8月15日丨华仁药业(300110.SZ)公布2025年半年度报告，上半年公司实现营业收入6.24亿元，同 比下降19.13%；归属于上市公司股东的净利润3733.29万元，同比下降49.01%；归属于上市公司股东的 扣除非经常性损益的净利润2768.92万元，同比下降59.17%；基本每股收益0.0316元。 ...

（文章来源：每日经济新闻） 华仁药业（SZ 300110，收盘价：3.52元）8月15日晚间发布半年度业绩报告称，2025年上半年营业收入 约6.24亿元，同比减少19.13%；归属于上市公司股东的净利润约3733万元，同比减少49.01%；基本每股 收益0.0316元，同比减少48.95%。 ...